MPH, Johns Hopkins Bloomberg School of Public Health, 1999
PharmD, Campbell University, 1992
Since coming to the Center for Immunization Research in 2008, my interests are primarily in program development, implementation, and management for early stage human vaccine trials. I have focused particularly on vaccines for flaviviruses (dengue virus and West Nile virus), but have also been involved in trials of vaccines against influenza, respiratory syncytial virus, and malaria. I provide training and oversight for members of the flavivirus vaccine team, and, in working with Dr. Durbin, have advanced our dengue virus vaccine from the earliest phase I studies through to phase 2 and 3 evaluation in dengue-endemic settings in Brazil and Viet Nam. As a Research Pharmacist I provide consultation on vaccine studies throughout the CIR, act as a liaison to the hospital’s Investigational Drug Service, and standardize treatment algorithms such as anaphylaxis management. In addition, I manage our Regulatory Compliance Team, which is responsible for communication with IRBs, FDA, Study Sponsors, and other regulatory bodies. In 2002, I founded the Johns Hopkins Hospital Moore Clinic’s Pharmacotherapy Clinic where I continue to provide HIV care on a weekly basis.
Honors and Awards
1988 Alpha Chi National Honor Society
1990 Omicron Delta Kappa National Leadership Society
1992 Hoechst-Roussel Excellence in Clinical Pharmacy Award
Most recent publications include:
- Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517. Epub 2016 Mar 16.
- Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16.
- Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015 Sep 1;212(5):702-10.
- Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in Flavivirus-naïve adults: a randomized, double-blind clinical trial. J Infect Dis. 2013 Mar 15;207(6):957-65.
- Byrnes AA, Harris DM, Atabani SF, Sabundayo BP, Langan SL, Margolick JB, Karp CL. Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy. J Leukoc Biol. 2008;84:1447-53
See all publications by Beulah P. Sabundayo